Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419

Last updated date
Study Location
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact
617-724-8770

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

617-724-8770

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schwannomatosis, Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients must have a confirmed diagnosis schwannomatosis by fulfilling either clinical or molecular diagnosis.

2. Age ≥ 18 years. Patients < 18 years are excluded since the safety profile of tanezumab in this population has not been determined.

3. ECOG performance status ≤2 or Karnofsky ≥60%

4. Participants must have normal organ and marrow function as defined per the full protocol

5. The subject's weight must be≥ 45 kg at Screening.

6. The subject must be willing to avoid prohibited pain medications (including non-steroidal anti-inflammatory drugs) throughout the duration of the study except as permitted per Protocol.

7. Subject must have moderate to severe pain secondary to schwannomatosis, defined as Score ≥5 on the Numeric Rating Scale-11 (NRS-11) at Screening.

8. Subject must have failure, intolerance, or contraindication to at least three standard of care therapies:

- Documented history indicating that NSAID therapy has not provided adequate pain relief or subject is unable to take NSAIDs due to contraindication or inability to tolerate.

- Documented history indicating that opioid treatment has not provided adequate pain relief or subject is unwilling to take opioids, or unable to take opioids due to contraindication or inability to tolerate

- Documented history indicating that neuropathic pain medications, such as gabapentin, pregabalin, or others, have not provided adequate pain relief or subject is unable to take these treatments due to contraindication or inability to tolerate.

9. Female subjects of childbearing potential and at risk for pregnancy (e.g., not abstinent) must agree to use 2 highly effective methods of contraception throughout the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous study medication.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Subjects with any of the following criteria: evidence of bilateral vestibular
schwannomas on imaging, a known germline pathogenic NF2 mutation, a first-degree
relative who meets diagnostic criteria for NF2, or have schwannomas limited to a
previous radiation field.


2. Subjects with intracranial meningioma associated with cerebral edema on neuroimaging.
Note: presence of intracranial meningioma itself is not an exclusion criterion.


3. Subjects who have had surgery, chemotherapy or radiotherapy within 4 weeks (6 weeks
for nitrosoureas or mitomycin C) for treatment of a painful schwannomatosis-related
tumor prior to entering the study or those who have not recovered from adverse events
due to agents administered more than 4 weeks earlier.


4. Participation in other studies involving investigational drug(s) (Phases 1-4) within
30 days (or 90 days for biologics) before Screening and/or during study participation.


5. Subjects receiving anticoagulation to treat an underlying medical condition.


6. Subject has a history of allergic or anaphylactic reaction to a therapeutic or
diagnostic monoclonal antibody or IgG fusion protein.


7. The subject's pain is related to a non-schwannomatosis cause such as prior cancer
therapy, infection, bowel obstruction/perforation, spinal cord compression, or
fracture or impending fracture of weight bearing bone.


8. The subject has a diagnosis of malignancy in the last 3 years (except for Gleason 6
prostate cancer, basal cell carcinoma or carcinoma in situ).


9. Use of concurrent adjuvant analgesics such as serotonin norepinephrine reuptake
inhibitors (SNRI), tricyclic antidepressants, anticonvulsant medication, or muscle
relaxants (unless the drugs were started at least 30 days prior to Screening and are
maintained at a stable dose).


10. Use of concurrent analgesic non-steroidal anti-inflammatory drugs (NSAIDs, including
selective COX-2 inhibitors) unless the subject is expected to be able to discontinue
these medications at least 2 weeks prior to treatment. Note: Subjects who take daily
low dose aspirin (≤ 325 mg as per local prescribing practice) therapy for
cardiovascular prophylaxis are not excluded from participation.


11. Diagnosis of osteoarthritis of the knee or hip as defined by the American College of
Rheumatology (ACR) combined clinical and radiographic criteria; Radiographic criteria
will be assessed by the Central Reader.


12. Use of concurrent corticosteroids (except for inhaled or topical corticosteroids as
needed for management of ongoing pulmonary or dermatologic conditions)


13. Subjects considered unfit for surgery, defined as Grade >3 on the American Society of
Anesthesiologists (ASA) physical classification system for surgery or subjects who
would not be willing to undergo joint replacement surgery if required.


14. Subjects with symptoms and radiographic findings (i.e. joint space narrowing,
osteophytes) consistent with osteoarthritis in the shoulder.


15. History of significant trauma or surgery to a major joint (e.g. hip, knee or shoulder)
within one year prior to Screening.


16. A history of osteonecrosis or osteoporotic fracture (i.e., a subject with a history of
osteoporosis and a minimally traumatic or atraumatic fracture).


17. Radiographic (x-ray) evidence of any of the following conditions as determined by the
central radiology reviewer at Screening: 1) rapidly progressive osteoarthritis, 2)
atrophic or hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4)
spontaneous osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic
fracture.


18. Subjects who have evidence of orthostatic hypotension based upon replicate orthostatic
blood pressure measurements at Screening.


19. Subjects with a total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at
Screening.


20. Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
diagnosis of stroke with residual deficits (e.g., aphasia, substantial motor or
sensory deficits), that would preclude completion of required study activities.


21. History, diagnosis, or signs and symptoms of clinically significant neurological


22. Subjects with a past history of carpal tunnel syndrome (CTS) with signs or symptoms of
CTS in the one year prior to Screening.


23. Subject with a history of significant alcohol, analgesic, or narcotic substance abuse
within the six months prior to Screening.


24. Subject who, in the judgement of the investigator, is expected to require a surgical
procedure during the duration of the study.


25. Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
antibody.


26. Subjects who are investigational site staff members directly involved in the conduct
of the trial and their family members, site staff members otherwise supervised by the
Investigator, or subjects who are Pfizer employees directly involved in the conduct of
the trial


27. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.


28. Pregnant females; breastfeeding females; females of childbearing potential not using
two (2) methods of highly effective contraception or not agreeing to continue two (2)
methods of highly effective contraception for 112 days (16 weeks) after last dose of
investigational product.


29. Any subject who, in the judgement of the investigator, is deemed inappropriate for
participation in the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Schwannomatosis, PainPhase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
NCT04163419
  1. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Official Title  ICMJE A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Brief Summary The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.
Detailed Description

Schwannomatosis is characterized by the predisposition to develop multiple schwannomas and, less commonly, meningiomas. Pain is the most frequent symptom reported by these patients, with 68% experiencing chronic pain.

The investigators propose to test the efficacy and tolerability of tanezumab as a treatment for schwannomatosis patients with chronic pain who have had inadequate pain relief in a randomized, placebo-controlled trial, which could form the basis of a larger, randomized controlled trial in the future.

The study is designed with a total duration of 281 days (40 weeks) and will consist of four periods: Pre-treatment, Double-Blind Treatment, Single Arm Treatment, and 24-Week Safety Follow-up. The Pre-Treatment Period lasting up to 30 days, followed by a Double-Blind Treatment Period lasting up to 8 weeks, followed by a Single Arm Treatment Period lasting up to 8 weeks, and a 24-Week Safety Follow-Up Period ending with the End of Study Visit at Week 40.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Schwannomatosis
  • Pain
Intervention  ICMJE
  • Drug: Tanezumab
    Tanezumab 10 mg SC
    Other Name: PF-04383119
  • Drug: Placebo
    Placebo 10 mg SC
Study Arms  ICMJE
  • Experimental: Arm A (treatment)
    Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
    Intervention: Drug: Tanezumab
  • Placebo Comparator: Arm B (placebo then treatment)
    Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
    Interventions:
    • Drug: Tanezumab
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 12, 2019)
46
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2024
Estimated Primary Completion Date June 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients must have a confirmed diagnosis schwannomatosis by fulfilling either clinical or molecular diagnosis.
  2. Age ? 18 years. Patients < 18 years are excluded since the safety profile of tanezumab in this population has not been determined.
  3. ECOG performance status ?2 or Karnofsky ?60%
  4. Participants must have normal organ and marrow function as defined per the full protocol
  5. The subject's weight must be? 45 kg at Screening.
  6. The subject must be willing to avoid prohibited pain medications (including non-steroidal anti-inflammatory drugs) throughout the duration of the study except as permitted per Protocol.
  7. Subject must have moderate to severe pain secondary to schwannomatosis, defined as Score ?5 on the Numeric Rating Scale-11 (NRS-11) at Screening.
  8. Subject must have failure, intolerance, or contraindication to at least three standard of care therapies:

    • Documented history indicating that NSAID therapy has not provided adequate pain relief or subject is unable to take NSAIDs due to contraindication or inability to tolerate.
    • Documented history indicating that opioid treatment has not provided adequate pain relief or subject is unwilling to take opioids, or unable to take opioids due to contraindication or inability to tolerate
    • Documented history indicating that neuropathic pain medications, such as gabapentin, pregabalin, or others, have not provided adequate pain relief or subject is unable to take these treatments due to contraindication or inability to tolerate.
  9. Female subjects of childbearing potential and at risk for pregnancy (e.g., not abstinent) must agree to use 2 highly effective methods of contraception throughout the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous study medication.

Exclusion Criteria:

  1. Subjects with any of the following criteria: evidence of bilateral vestibular schwannomas on imaging, a known germline pathogenic NF2 mutation, a first-degree relative who meets diagnostic criteria for NF2, or have schwannomas limited to a previous radiation field.
  2. Subjects with intracranial meningioma associated with cerebral edema on neuroimaging. Note: presence of intracranial meningioma itself is not an exclusion criterion.
  3. Subjects who have had surgery, chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) for treatment of a painful schwannomatosis-related tumor prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  4. Participation in other studies involving investigational drug(s) (Phases 1-4) within 30 days (or 90 days for biologics) before Screening and/or during study participation.
  5. Subjects receiving anticoagulation to treat an underlying medical condition.
  6. Subject has a history of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein.
  7. The subject's pain is related to a non-schwannomatosis cause such as prior cancer therapy, infection, bowel obstruction/perforation, spinal cord compression, or fracture or impending fracture of weight bearing bone.
  8. The subject has a diagnosis of malignancy in the last 3 years (except for Gleason 6 prostate cancer, basal cell carcinoma or carcinoma in situ).
  9. Use of concurrent adjuvant analgesics such as serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants, anticonvulsant medication, or muscle relaxants (unless the drugs were started at least 30 days prior to Screening and are maintained at a stable dose).
  10. Use of concurrent analgesic non-steroidal anti-inflammatory drugs (NSAIDs, including selective COX-2 inhibitors) unless the subject is expected to be able to discontinue these medications at least 2 weeks prior to treatment. Note: Subjects who take daily low dose aspirin (? 325 mg as per local prescribing practice) therapy for cardiovascular prophylaxis are not excluded from participation.
  11. Diagnosis of osteoarthritis of the knee or hip as defined by the American College of Rheumatology (ACR) combined clinical and radiographic criteria; Radiographic criteria will be assessed by the Central Reader.
  12. Use of concurrent corticosteroids (except for inhaled or topical corticosteroids as needed for management of ongoing pulmonary or dermatologic conditions)
  13. Subjects considered unfit for surgery, defined as Grade >3 on the American Society of Anesthesiologists (ASA) physical classification system for surgery or subjects who would not be willing to undergo joint replacement surgery if required.
  14. Subjects with symptoms and radiographic findings (i.e. joint space narrowing, osteophytes) consistent with osteoarthritis in the shoulder.
  15. History of significant trauma or surgery to a major joint (e.g. hip, knee or shoulder) within one year prior to Screening.
  16. A history of osteonecrosis or osteoporotic fracture (i.e., a subject with a history of osteoporosis and a minimally traumatic or atraumatic fracture).
  17. Radiographic (x-ray) evidence of any of the following conditions as determined by the central radiology reviewer at Screening: 1) rapidly progressive osteoarthritis, 2) atrophic or hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.
  18. Subjects who have evidence of orthostatic hypotension based upon replicate orthostatic blood pressure measurements at Screening.
  19. Subjects with a total impact score of >7 on the Survey of Autonomic Symptoms (SAS) at Screening.
  20. Diagnosis of a transient ischemic attack in the 6 months prior to Screening or diagnosis of stroke with residual deficits (e.g., aphasia, substantial motor or sensory deficits), that would preclude completion of required study activities.
  21. History, diagnosis, or signs and symptoms of clinically significant neurological
  22. Subjects with a past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one year prior to Screening.
  23. Subject with a history of significant alcohol, analgesic, or narcotic substance abuse within the six months prior to Screening.
  24. Subject who, in the judgement of the investigator, is expected to require a surgical procedure during the duration of the study.
  25. Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor antibody.
  26. Subjects who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the trial
  27. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  28. Pregnant females; breastfeeding females; females of childbearing potential not using two (2) methods of highly effective contraception or not agreeing to continue two (2) methods of highly effective contraception for 112 days (16 weeks) after last dose of investigational product.
  29. Any subject who, in the judgement of the investigator, is deemed inappropriate for participation in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Scott R Plotkin, MD, PhD617-724-8770[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04163419
Other Study ID Numbers  ICMJE 2019P003201
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Scott R. Plotkin, MD, PhD, Massachusetts General Hospital
Study Sponsor  ICMJE Massachusetts General Hospital
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Scott R PlotkinMassachusetts General Hospital
PRS Account Massachusetts General Hospital
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP